EverolimusHOUGHTON, Peter J.Clinical cancer research (Print). 2010, Vol 16, Num 5, pp 1368-1372, issn 1078-0432, 5 p.Article

Temsirolimus, an Inhibitor of Mammalian Target of RapamycinRINI, Brian I.Clinical cancer research. 2008, Vol 14, Num 5, pp 1286-1290, issn 1078-0432, 5 p.Article

mTOR Signaling Pathway and mTOR Inhibitors in Cancer TherapyGOMEZ-PINILLOS, Alejandro; FERRARI, Anna C.Hematology/oncology clinics of North America. 2012, Vol 26, Num 3, issn 0889-8588, vii, 483-505 [24 p.]Article

Preclinical evidences suggest new treatment options for endocrine disorders : Pasireotide (SOM230) and Everolimus (RAD001)SCHMID, H. A.Annales d'endocrinologie. 2008, Vol 69, Num 2, pp 162-163, issn 0003-4266, 2 p.Conference Paper

Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATRQINGSONG LIU; CHUNXIAO XU; ERCAN, Dalia et al.Cancer research (Chicago, Ill.). 2013, Vol 73, Num 8, pp 2574-2586, issn 0008-5472, 13 p.Article

Inhibiteurs de mTOR: de l'explication biologique à l'application thérapeutique en hématologie = m-TOR inhibitors: biology and use in the treatment of haematological diseasesBALSAT, Marie; CORNILLON, Jérôme.Bulletin du cancer. 2011, Vol 98, Num 8, pp 935-943, issn 0007-4551, 9 p.Article

Combination of PI3K/mTOR Inhibitors: Antitumor Activity and Molecular CorrelatesMAZZOLETTI, Marco; BORTOLIN, Francesca; BRUNELLI, Laura et al.Cancer research (Chicago, Ill.). 2011, Vol 71, Num 13, pp 4573-4584, issn 0008-5472, 12 p.Article

Targeting the mTOR kinase domain: the second generation of mTOR inhibitorsZHANG, Yan-Jie; YANWEN DUAN; ZHENG, X. F. Steven et al.Drug discovery today. 2011, Vol 16, Num 7-8, pp 325-331, issn 1359-6446, 7 p.Article

Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComaITALIANO, A; DELCAMBRE, C; HOSTEIN, I et al.Annals of oncology. 2010, Vol 21, Num 5, pp 1135-1137, issn 0923-7534, 3 p.Article

CDC25B Mediates Rapamycin-Induced Oncogenic Responses in Cancer CellsCHEN, Run-Qiang; YANG, Qing-Kai; LU, Bing-Wen et al.Cancer research (Chicago, Ill.). 2009, Vol 69, Num 6, pp 2663-2668, issn 0008-5472, 6 p.Article

Intravenous Temsirolimus in Cancer Patients: Clinical Pharmacology and Dosing ConsiderationsBONI, Joseph P; HUG, Bruce; LEISTER, Cathie et al.Seminars in oncology. 2009, Vol 36, Num 6, issn 0093-7754, S18-S25, SUP3Article

The Macrolide Everolimus Forms an Unusual Metabolite in Animals and Humans : Identification of a Phosphocholine EsterZOLLINGER, Markus; SAYER, Claudia; DANNECKER, Robert et al.Drug metabolism and disposition. 2008, Vol 36, Num 8, pp 1457-1460, issn 0090-9556, 4 p.Article

The Impact of mTOR Inhibitors on the Development of MalignancyGEISSLER, E. K.Transplantation proceedings. 2008, Vol 40, Num 10, issn 0041-1345, S32-S35, SUPConference Paper

Control of carcinoid syndrome with everolimusCAPDEVILA, J; DIEZ MIRANDA, I; OBIOLS, G et al.Annals of oncology. 2011, Vol 22, Num 1, pp 237-239, issn 0923-7534, 3 p.Article

Paronychia and Pyogenic Granuloma Induced by New Anticancer mTOR InhibitorsSIBAUD, Vincent; DALENC, Florence; MOUREY, Loic et al.Acta dermato-venereologica. 2011, Vol 91, Num 5, pp 584-585, issn 0001-5555, 2 p.Article

Inhibition of induced autophagy increases apoptosis of Nara-H cellsNAKAMURA, Osamu; HITORA, Toshiaki; AKISUE, Toshihiro et al.International journal of oncology. 2011, Vol 39, Num 6, pp 1545-1552, issn 1019-6439, 8 p.Article

The Role of mTOR Inhibitors in the Management of Posttransplant MalignancyMONACO, Anthony P.Transplantation. 2009, Vol 87, Num 2, pp 157-163, issn 0041-1337, 7 p.Article

Everolimus de novo in liver transplantationCALMUS, Y; DURRBACH, A.Gastroentérologie clinique et biologique. 2009, Vol 33, issn 0399-8320, S247-S252, SUP4Article

In vitro metabolic study of temsirolimus : Preparation, isolation, and identification of the metabolitesPING CAI; TSAO, Rushung; RUPPEN, Mark E et al.Drug metabolism and disposition. 2007, Vol 35, Num 9, pp 1554-1563, issn 0090-9556, 10 p.Article

NVP-BEZ235, a Dual P13K/mTOR Inhibitor, Prevents P13K Signaling and Inhibits the Growth of Cancer Cells with Activating P13K MutationsSERRA, Violeta; MARKMAN, Ben; MAIRA, Michel et al.Cancer research (Chicago, Ill.). 2008, Vol 68, Num 19, pp 8022-8030, issn 0008-5472, 9 p.Article

Sirolimus (rapamycin) : From the soil of Easter Island to a bright futurePAGHDAL, Kapila V; SCHWARTZ, Robert A.Journal of the American Academy of Dermatology. 2007, Vol 57, Num 6, pp 1046-1050, issn 0190-9622, 5 p.Article

Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase InhibitorMALLON, Robert; FELDBERG, Larry R; HOLLANDER, Irwin et al.Clinical cancer research (Print). 2011, Vol 17, Num 10, pp 3193-3203, issn 1078-0432, 11 p.Article

Evaluating Temsirolimus Activity in Multiple Tumors: A Review of Clinical TrialsDANCEY, Janet E; CURIEL, Rafael; PURVIS, Joseph et al.Seminars in oncology. 2009, Vol 36, Num 6, issn 0093-7754, S46-S58, SUP3Article

Corneal Permeation Studies of Everolimus MicroemulsionBASPINAR, Yuecel; BERTELMANN, Eckart; PLEYER, Uwe et al.Journal of ocular pharmacology and therapeutics. 2008, Vol 24, Num 4, pp 399-402, issn 1080-7683, 4 p.Article

Rapamycin prevents thyroid hormone-induced cardiac hypertrophyKUZMAN, James A; O'CONNELL, Timothy D; GERDES, A. Martin et al.Endocrinology (Philadelphia). 2007, Vol 148, Num 7, pp 3477-3484, issn 0013-7227, 8 p.Article